Xeris Biopharma (XERS) to Release Quarterly Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Xeris Biopharma to post earnings of ($0.07) per share and revenue of $57.61 million for the quarter.

Xeris Biopharma Stock Up 5.1 %

Shares of XERS stock traded up $0.23 during trading hours on Friday, hitting $4.71. 2,188,735 shares of the company's stock traded hands, compared to its average volume of 1,903,077. Xeris Biopharma has a 12 month low of $1.72 and a 12 month high of $6.07. The stock has a market cap of $736.57 million, a PE ratio of -10.47 and a beta of 1.10. The stock's 50 day simple moving average is $4.57 and its 200 day simple moving average is $3.79.

Analyst Ratings Changes

A number of equities analysts recently weighed in on XERS shares. Piper Sandler reissued a "neutral" rating and set a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Jefferies Financial Group reissued a "buy" rating and issued a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. HC Wainwright restated a "buy" rating and set a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Leerink Partners lifted their target price on Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. Finally, Craig Hallum increased their price target on Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $6.10.

Insider Activity at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.56% of the stock is currently owned by corporate insiders.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.